Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vericel (VCEL) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Vericel (VCEL) over the last 12 years, with Sep 2025 value amounting to $2.6 million.

  • Vericel's Capital Expenditures fell 86.45% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.8 million, marking a year-over-year decrease of 33.19%. This contributed to the annual value of $64.0 million for FY2024, which is 219.66% up from last year.
  • According to the latest figures from Q3 2025, Vericel's Capital Expenditures is $2.6 million, which was down 67.66% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Vericel's Capital Expenditures registered a high of $19.4 million during Q3 2024, and its lowest value of $991,000 during Q4 2021.
  • In the last 3 years, Vericel's Capital Expenditures had a median value of $8.1 million in 2025 and averaged $9.9 million.
  • As far as peak fluctuations go, Vericel's Capital Expenditures spiked by 565.68% in 2021, and later slumped by 86.45% in 2025.
  • Over the past 5 years, Vericel's Capital Expenditures (Quarterly) stood at $991,000 in 2021, then spiked by 36.53% to $1.4 million in 2022, then skyrocketed by 479.08% to $7.8 million in 2023, then surged by 75.97% to $13.8 million in 2024, then tumbled by 86.45% to $2.6 million in 2025.
  • Its Capital Expenditures stands at $2.6 million for Q3 2025, versus $8.1 million for Q2 2025 and $14.2 million for Q1 2025.